

## Hull and East Riding Prescribing Committee Minutes –CONFIRMED

<b>Date / Time</b>	Wednesday 28 <sup>th</sup> September 2016
<b>Venue</b>	Meeting Room 1, Health House, Willerby
<b>Chair</b>	Dr Z Norris, GP Prescribing Lead, Hull CCG
<b>Notes / Action Points</b>	Mrs S Greene, Senior Pharmacy Technician – Formulary/Interface, HEY.
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Dr M Miller, Senior Principal Pharmacist - Interface, HEY Mr G Hill, Senior Pharmacist, CHCP Prof A Morice, Professor of Respiratory Medicine Dr S Raise, GP Prescribing Lead, ER Mr S Gaines, Senior Principal Pharmacist, HEY Dr A Jeffreys, General Practitioner, LMC Mrs J Moore, None Medical Prescriber, HFT (until 2pm) Ms L Lyle, Senior Pharmacist, Hull NECS Ms J Stark, Senior Pharmacist, HFT Dr W Chong, Chief Pharmacist, HFT Phil Davis, Head Of Primary Care, Hull, CCG Dr A Saxena, LMC, GP in Goole
-------------------	--

### Apologies

Dr S Roberts, Medical Secretary, Secretariat for Humberside LMC
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HEY
Mr K McCorry, Locality Pharmacist, NECS

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2016.09.01	Apologies	As above.				
2016.07.02	Declarations of Interest	None declared				
2016.07.03	Minutes of the previous meeting	Accepted as a true record				
2016.07.04	Action Tracker	<p>Shared Care Framework Discharge &amp; Referral KMc has discussed with contracting. Specific examples have been requested. Agreed that contact number should be added to SCF when patient needs referral back into the system. Identify specialities on discharging required – LMC has requested. Defer to next meeting</p> <p>Medicines Optimisation Concerns LL is liaising with Emma Owen who is leading for both CCG's. To feedback gaps in commissioning for medicines optimisation reviews in primary care.</p> <p>SG had raised at Thrombosis Committee. Team had agreed that weight/renal function should be added to treatment requests. Dr Saleh to cascade new procedure to medics via letter.</p> <p>Feedback from Commissioning Groups. MM has informed HEY ophthalmologists of commissioners decision regarding AREDS and AREDS 2, ophthalmology was not happy with this decision. Both CCG's agreed that there could be no appeal against the decision, but it was possible to appeal against the process.PALS system in place for patients.</p>	<p>HEY/HFT need to cost this and can feedback</p> <p>Update next time</p> <p>Action complete</p>	<p>Action complete</p>	<p>WC/MM</p> <p>LL</p> <p>SG</p>	<p>Nov 16</p> <p>Jan 16</p> <p>Sept 16</p> <p>Sept 16</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>Clinical Network Guidance Acetylcholinesterase Inh <a href="#">TA217</a> recommends that non specialist can prescribe specific dementia medicines if they have taken advice from specialist (list of specialists contained in TA, not only secondary care). Network guidance also recommends changes in patient groups requiring ECG, as discussed at previous meeting</p> <p>Prescribing Issues Relating to Epoetins KMc will look at what provision is available in ER and discuss next time.</p> <p><b>Decision making process</b> – Decisions at meetings need both clinical and financial input. Phil Davis had attended for the Hull CCG. Status to be downgraded to Red/Amber – work in progress.</p> <p><b>Prescribing issues relating to Epoetins</b> – Clarification need re Phlebotomy results. SR to speak to KMc. MM to discuss with pathology</p> <p><b>Traffic light status / Guidelines</b> Traffic light status – feedback requested from commissioners Shared care frameworks / prescribing guidelines – sent to commissioners for approval</p> <p><b>Sacubitril valsartan</b> – PIL written, on agenda</p> <p><b>Shared care farmeworks/ prescribing guidelines</b> All approved guidelines added to website</p> <p><b>Prescribing guidelines</b> – lidocaine. Discussed with commissioners – on agenda</p> <p><b>Regional Medicines Optimisation Committees</b></p>			MM	Nov 16
			KMc to feedback next time		KMc	Sept 16
				Status downgraded to Red/Amber	ZN/SR	Nov 16
					SR/MM	Nov 16
			Action complete	No further action	/KMc LL	Sep 16
			Action complete	No further action	MM	Sep 16
			Action complete	No further action	MM	Sep 16
			Action complete	No further action	MM	Sep 16

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>Details of stakeholder consultation circulated by MM</p> <p><b>NICE/NHSE Guidance – SSC1620</b> MM has requested official feedback from LMC who are discussing with CCG and NHS England</p> <p><b>Transfer of Care</b> MM to obtain specific examples of issues with med calls. MM has requested but no examples raised. To put back on agenda if examples received.</p> <p><b>Branded Generics</b> LL has provided MM/WH with link to NECS communication form</p> <p><b>Communication Received</b> Medicines with more than one traffic light status to be added to joint formulary agenda. Still to arrange next Joint Formulary meeting</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Add to JF agenda</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>Arrange JF meeting</p>	<p>MM</p> <p>MM</p> <p>MM</p> <p>MM</p> <p>MM</p>	<p>Sep 16</p> <p>Sep 16</p> <p>Sep 16</p> <p>Sep 16</p> <p>Sep 16</p>
2016.9.5	<p><b>Traffic light status</b></p> <p> Agenda item 5a HEY D&amp;T HFT DTC briefing</p>	<p>a. HEY D &amp; T – Please see attached. These drugs are all NHS England commissioned. All Red</p> <p>b. HFT DTC – Paliperidone palmitate 3 monthly – To be shared care with HFT. Costings not affected. LL to put in Newsletter. Verbal agreement. Joint Formulary to be updated.</p> <p>c. CHCP Therapeutics Committee – nothing to report</p>	Approved as listed	Add to joint formulary	<p>Sue G</p> <p>LL</p> <p>SG</p>	<p>Nov 16</p> <p>Nov 16</p> <p>Nov 16</p>
2016.9.06	<b>Feedback from Commissioning Groups (Hull and ER CCG)</b>	All drugs discussed at the July HERPC meeting were approved at the Commissioning Groups for Hull / ERY CCG's.	Approved	Update HERPC website	Sue G	Nov 16

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2016.09.07	Shared Care Frameworks – Prescribing Guidelines	<p><b>a. Sacubitril Valsartan guidelines including PIL</b> MM to amend wording on the guidelines. AG to e-mail narrative.</p> <p><b>b. Liothyronine guideline</b> Patients reviewed as they come in. MM to put notification in GP newsletter</p>	<p>Approved subject to updated wording</p> <p>Approved</p>	Update PIL	MM	Nov 16
		<p><b>c. Tolvaptan guideline</b> NICE TA already approved for Renal use – agreed Red Drug. Approved subject to amendments forward to ZR, SR, KMc, and PD in the CCG's.</p> <p><b>d. Guanfacine shared care framework</b> Approved subject to review of wording for indication by specialist teams. Problems related to lack of commissioned service for adults to be escalated to CCG's.</p> <p><b>e. Type 2 diabetes algorithm</b> Approved</p>	<p>Approved subject to rewording</p> <p>Approved subject to rewording</p> <p>Approved</p>	<p>MM to update document and send to CCG's</p> <p>HFT/CHCP to update</p> <p>Escalate to CCGs</p> <p>Add all approved guidelines to website</p>	<p>MM</p> <p>JS/GH</p> <p>ZN/SR</p> <p>Sue G</p>	<p>Nov 16</p> <p>Nov 16</p> <p>Nov 16</p> <p>Nov 16</p>
2016.09.08	Outpatient treatment request forms	The team discussed concerns around illegible prescriptions. Main concerns being raised with Spire and Cardiology hand written scripts – feedback required from LMC. MM to raise with Health Group Governance meetings and Lorenzo Project Board	Escalate within HEY	MM to escalate	MM	Nov 16
2016.09.10	Changes to HEY Interface Staff	MM introduced Sue Greene who has taken over Wendy Hornsby's role as Formulary/Interface Technician on a trial basis. MM also advised that she has accepted a new post within HEY as Senior Principal Pharmacist – Education & Training, Pharmacy Lead for Medicine HG. The Interface Pharmacist post has been submitted to the HEY Trust vacancy panel – MM will continue to support Interface until	Noted	No further action		

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		further notice				
2016.09.11	Governance	<b>Methotrexate Incidents</b> Recent incidents have highlighted an issue regarding incorrect frequency of Methotrexate doses in Rheumatology patients.	Alert to be circulated in all areas		All	
2016.09.12	Communication Received	None received				
2016.09.13	Primary Care rebate scheme - standing item	Stalevo alternatives to be discussed at MMIG.	Discuss at MMIG	Add to MMIG agenda	SG	Nov 16
2016.09.14	Additional Minutes for Information	<ul style="list-style-type: none"> <li>a) MMIG (May)</li> <li>b) HEY D&amp;T (May, Junel)</li> <li>c) HFT DTC (April)</li> <li>d) Formulary Sub Group (May)</li> </ul>	Noted	No further action		
2016.09.15	AOB	The pilot to provide a portal facility by HEY to GP's had gone live. Only 40 queries had been logged by primary care pharmacies, and mostly around quality of discharges. This information is to be fed back to the Trust Safe Medication Practice Committee	Keep portal open for now, and review once permanent Interface staff in place			
2016.07.15	Date and Time of Next Meeting	Wednesday 23 <sup>rd</sup> November 2016 1 – 3pm TBC				